News Another AIM defection as BiVictriX plans to delist The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.